Where Will CRISPR Therapeutics Stock Be in 2030?
The company's expertise in gene editing could lead to more breakthroughs.
CRISPR Therapeutics (CRSP -4.41%) has seen a decline of approximately 47% in its stock since mid-October 2021, while the S&P 500 has gained almost 73%. However, the biotech has made significant progress in clinical and regulatory approvals over the past five years. In 2023 and early 2024, CRISPR Therapeutics received approval for Casgevy, a CRISPR-based gene-editing therapy for transfusion-dependent beta-thalassemia and sickle cell disease, which was the first of its kind to gain approval.
This milestone is crucial as it marks the company's transition to a commercial biotech and validates its platform. Despite not seeing much progress since Casgevy's approval, CRISPR Therapeutics has several promising pipeline candidates, such as CTX310 for reducing LDL cholesterol and triglycerides, zugo-cel for autoimmune diseases and blood cancers, and CTX611, an anticoagulant with a once-daily administration.
If CRISPR Therapeutics successfully launches these therapies by 2030, its financial performance and share price are expected to significantly improve. However, there are substantial risks, including clinical trial failures and the high cost of manufacturing and administering gene-editing medicines. Investors should carefully consider these risks before investing in CRISPR Therapeutics.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
